Chickadee Biomedicines, Inc. has announced the successful completion of a private offering, raising a total of $1 million. This funding is crucial for the company as it looks to bolster its operations and support its executive team.

The offering, filed with the SEC on November 10, 2026, allows Chickadee to utilize the proceeds for general corporate and working capital purposes. This includes the payment of salaries for its executive officers, as disclosed to investors.

Background

Chickadee Biomedicines, Inc. is a biotechnology company incorporated in Delaware. The company is relatively new, having been established in 2025. Its business address is located at 626 1st Avenue, New York, NY. The firm does not currently have any publicly traded ticker symbols or exchange listings.

What the Filing Says

The SEC filing indicates that the offering falls under Rule 506(b), which provides a safe harbor for private offerings. The document states, "Proceeds will be used for Issuer's general corporate and working capital purposes, which will include payment of salary of executive officer in the ordinary course of business as disclosed to investors." This highlights the company's focus on maintaining operational stability.

Impact

This funding round may positively impact the company's ability to execute its business strategy and sustain its operations. The filing notes that there are currently two investors involved in this offering, and it does not include non-accredited investors. This suggests a targeted approach to fundraising, likely focusing on seasoned investors familiar with the biotechnology landscape.

What's Next

The filing does not say what happens next.